This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
The ECB is trying to keep Greece in line, and this has sent a ripple through equity markets. The move has crushed Greece under the weight of its own debt. Yanis Varoufakis has learned that he can’t have his cake and eat it too, and in order for the ECB to back Greece the austerity scheme must be kept to schedule.
Tesco is in trouble again after the Groceries Code Adjudicator launched an investigation into the supermarket's suspicious payments to suppliers. Although the GCA investigation is not as consequential as a Serious Fraud Office investigation, it strips away another layer of confidence traders have in the supermarket chain.
Shares in AstraZeneca have taken a tumble after the drug company revealed a fourth-quarter loss, and the dreary outlook only compounded the company’s problems. AstraZeneca fended off Pfizer’s takeover attempt last year, and now the company is going on its own acquisition trail by taking over Actavis’s respiratory drug division in North America.
We are expecting the Dow Jones to open 10 points higher at 17,683, as the US benchmark is gaining back the momentum it lost last night due to the ECB's actions in relation to Greece. The jobless claims report at lunchtime will set the mood for the non-farm payrolls announcement tomorrow. Traders' expectations have been lowered in light of the ADP report yesterday.